Last reviewed · How we verify

NCT05231252

The Effect of Direct Cyclophotocoagulation Using Endolaser in Silicon Induced Glaucoma: a Pilot Study.

Completed NA Last updated 23 November 2022
What this trial tests

NA trial testing Cyclophotocoagulation in Glaucoma in 10 participants. Completed in 1 January 2022.

Timeline
1 June 2021
Primary endpoint
1 January 2022
1 January 2022

Quick facts

Lead sponsorKafrelsheikh University
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationnon randomized
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment10
Start date1 June 2021
Primary completion1 January 2022
Estimated completion1 January 2022
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Kafrelsheikh University

Who can join

18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Transcleral cyclophotocoagulation has been used to treat glaucoma secondary to silicone oil

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Cyclophotocoagulation

Trials testing the same drug.

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

Other Kafrelsheikh University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05231252.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing